欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
Certification ofsuitability to the Monographs of the European PharmacopoeiaImplementation ofICH Q3D in the Certification ProcedureCEP程序中ICH Q3D的实施
译文仅供参考
注:原文中final substance通指原料药及其它药用物质,在翻译中为简化,均译为原料药。
1. Background背景 The ICH Q3D guideline on elemental impurities iseffective in the European Union from June 2016 for new marketing authorisationapplications and from December 2017 for authorised medicinal products. ICH Q3D元素杂质指南自2016年6月起在欧盟范围内对新上市许可申报开始生效,自2017年12月起对已批准的药品生效。 This document is intended to serve as guidance on how toimplement ICH Q3D in the procedure for “Certification of Suitability to themonographs of the European Pharmacopoeia” (CEP). 本文件意在作为指南,指导在CEP程序中如何实施ICH Q3D。 ICH Q3D covers 24 elements (classified under thefollowing classes 1, 2A, 2B and 3) and gives permitted daily exposure (PDE) indrug products. ICH Q3D is not limited to reagents and catalysts in drugsubstance or excipients, but also considers all contributions from manufactureincluding manufacturing equipment, water and container-closure system. ICH Q3D覆盖了24种金属(分为1类、2A类、2B类和3类),并且给出了其在药品中的允许日暴露量(PDE)。ICH Q3D并不仅局限于原料药和辅料中的试剂和催化剂,同时也考虑到了所有生产中可能引入的情况,包括生产设备、水和容器密闭系统。 The ICH Q3D guideline emphasises developing a risk-basedcontrol strategy to limit elemental impurities which is summarised in anappropriate “Risk Management Summary” document. ICH Q3D指南强调了开发基于风险的控制策略来限制元素杂质,该方法在“风险管理总结”文件里进行汇总。 2. Scope 范围 This document describes the policy for elementalimpurities in substances covered by a Certificate of Suitability to themonographs of the European Pharmacopoeia (CEP). 本文描述了CEP证书所覆盖的原料药中元素杂质的政策。 This document covers pharmaceutical substances introducedin medicinal products within the scope of ICH Q3D. For products outside thescope of Q3D, the applicant should control adequately the levels of elementalimpurities in their substance. 本文覆盖了被引入ICH Q3D范围内药品的原料药。对于不在Q3D范围内的药品,申报者应对其原料药中的元素杂质进行充分控制。 The reference documents taken into consideration whenelaborating this policy are: 在起草本方针政策时所考虑的参考文件有: ― ICH guideline Q3D on elemental impurities(EMA/CHMP/ICH/353369/2013) and associated ICH training modules ― ICH Q3D元素杂质指南(EMA/CHMP/ICH/353369/2013)和相关的ICH培训模块 ― Elemental Impurities in marketed products. Recommendationsfor implementation (EMA/CHMP/QWP/109127/2015) ― 已上市药品中的元素杂质,实施建议(EMA/CHMP/QWP/109127/2015) ― Implementation strategy of ICH Q3D guideline – Draft(EMA/404489/2016) ― ICH Q3D指南实施策略---草案(EMA/404489/2016) This policy is applicable to new, renewed and revisedCEPs granted from the 1st September 2016 (provided the applicant/holderhas made reference to ICH Q3D principles in their application). 本方针政策适用于自2016年9月1日起颁发的新的、更新的以及修订的CEP(如果申报者/持有人在其申报中引用ICH Q3D原则的话)。
|